Lund, Sweden, June 18, 2020 /PRNewswire/ -- BioInvent
International AB ("BioInvent") (OMXS: BINV) today announces,
on behalf of the nomination committee and major shareholders, the
proposal to elect Dr. Thomas Hecht
as new Board member at the Extraordinary General
Meeting on July 3, 2020, in
accordance with the convening notice to the Extraordinary General
Meeting.
Further to the investment made by HBM Healthcare Investments
ltd. ("HBM") in the directed share issue announced by
BioInvent on June 9, 2020, the
nomination committee and major shareholders of BioInvent have
proposed that the Board of Directors of BioInvent shall be
increased by one Board member and proposes that Dr. Thomas Hecht is elected as new Board member of
BioInvent.
Dr. Thomas
Hecht (born 1951), MD, is Managing Partner at HHC
Healthcare Consulting since 2002, where he consults and advices
biotechnology, pharmaceutical and investment companies in overall
strategies, product and portfolio analysis with focus on medical
(clinical development), medical-marketing (medical affairs),
marketing and sales. Dr. Hecht was previously Vice President
Marketing at Amgen Europe. A seasoned manager and industry
professional, he held various positions of increasing
responsibility in clinical development, medical affairs and
marketing at Amgen between 1989 and 2002. Prior to joining the
biopharmaceutical industry, he was certified in internal medicine
and served as Co-Head of the Program for Bone Marrow
Transplantation at the University of Freiburg,
Germany. Dr. Thomas Hecht is
Chairman of the Board of Orion Biotechnology Ltd., Canada, Affimed N.V., Germany and Aelix Therapeutics S.L.,
Spain and Board member in Kuur
Therapeutics Ldt., Great
Britain/US. Dr. Thomas Hecht
is independent in relation to the company, the executive management
and major shareholders.
About BioInvent
BioInvent International AB (OMXS: BINV) is a clinical stage
company that discovers and develops novel and first-in-class
immuno-modulatory antibodies for cancer therapies, with two ongoing
programs in Phase l/ll clinical trials for the treatment of
hematological cancer and solid tumors, respectively. Two
preclinical programs in solid tumors are expected to enter clinical
trials by the end of 2020. The Company's validated, proprietary
F.I.R.S.T.™ technology platform simultaneously identifies both
targets and the antibodies that bind to them, generating many
promising new drug candidates to fuel the Company's own clinical
development pipeline or for additional licensing and
partnering.
The Company generates revenues from research collaborations and
license agreements with multiple top-tier pharmaceutical companies,
as well as from producing antibodies for third parties in the
Company's fully integrated manufacturing unit. More information is
available at www.bioinvent.com.
For further information, please contact:
Martin Welschof,
CEO
+46
(0)46-286-85-50
martin.welschof@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No.:
556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46-286-85-50
www.bioinvent.com
This information was brought to you by Cision
http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/583/3137758/1266676.pdf
|
Press release
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/proposal-for-a-new-board-member-to-be-elected-at-the-extraordinary-general-meeting-on-july-3-2020-301079555.html
SOURCE BioInvent